ATLANTA, April 23, 2007 (PRIME NEWSWIRE) -- Market Pulse announces that Human BioSystems (OTCBB:HBSC) is now profiled on their web site located at www.Market-Pulse.com. Human BioSystems is a leader in the development of preservation platform technologies that provide safe, high quality, and longer shelf lives for organs, tissue, cells and other biomaterials that are used in saving lives. Human BioSystems' proprietary preservation systems for initial products consist of non-toxic liquid solutions, proprietary protocols and solutions. These systems do not employ toxic preservatives or special cryogenic techniques or complex equipment. HBSC's technology and equipment may allow blood centers and hospitals to recover more than $500 million in lost revenue annually in North America, Western Europe and Japan. The company's target customers include blood banks, hospitals, clinics, and similar organizations. Market Pulse's profile focuses on the company, its technology and products, the biomedical markets, the alternative energy market (HBS BioEnergy), recent developments and the future outlook. Individuals interested in more information on the company can view the profile at http://www.market-pulse.com/hbscprofile.htm.
HBSC specializes in the development of proprietary above zero (HBS-AZ) and below zero (HBS-BZ) organ and tissue preservation systems and methods for preserving blood platelets. HBSC has five issued patents (with others pending) for technologies that preserve platelets and organs such as the kidney, heart, liver, and lung. The company's unique patent-pending technology could double the storage period for platelets, may dramatically reduce bacterial growth and may maintain better platelet functionality. The company has been successful in preserving blood platelets for ten days under refrigeration while maintaining cell structure and morphology, which has never been done before to HBSC's knowledge. HBSC is expected to be a major supplier to the industry with their improved platelet storage technology. The company estimates a potential multi-billion dollar market demand for its platelet and organ preservation system, coupled with the post-transplant technology, once fully developed and commercialized. HBSC is looking for additional products that are close to commercialization to add to its pipeline.
According to Bernard R. Schmitt, CEO of Market Pulse, "We are very excited to introduce Human BioSystems to the investment community. Human BioSystems has made excellent fundamental strides over the last few months. HBSC is poised to become a significant player in the biomedical and bioenergy industries." Bernard Schmitt also noted that, "Human BioSystems has pioneered revolutionary technologies that may forever change both the blood banking and organ and tissue transplantation industries. Developed after many years of research into extending the preservation periods of biological materials, these cutting-edge technologies may soon be available to save potentially thousands of lives and hundreds of millions of dollars."
The Human BioSystems' biological preservation program is a technologically advanced preservation and storage system intended to extend the shelf life of platelets, the congealing component of blood. Cancer patients undergoing chemotherapy treatments are the predominant recipients of platelet transfusions. Other persons that often require platelet transfusions are patients undergoing extensive surgery, trauma or burn victims and individuals with platelet deficiencies such as caused by bone marrow disease. Human BioSystems has achieved several major technical breakthroughs in the field of organ preservation. The basic HBSC organ technology and methodology has displayed amazingly effective breakthroughs. HBSC technologies may extend an organ's storage life while simultaneously maintaining the quality and viability of donated organs, offering more opportunities for life to the many patients who are on a transplant waiting list.
Human BioSystems' wholly owned subsidiary HBS BioEnergy (HBSE) is engaged in the business of bio-fuels production, with a team focused on locating, constructing and operating bio-fuels facilities using cutting-edge technologies. The company commenced operations in September of 2006, pursuant to a definitive agreement signed between HBS BioEnergy and EXL III Group Corporation. HBS BioEnergy recently signed a land lease with the Port of Morrow in Boardman, Oregon for the proposed construction of both an ethanol plant and a bio-diesel facility. Both are considered renewable fuel facilities.
Both projects will take advantage of HBS BioEnergy's recent joint venture and affiliation with Agri-Mass Enviro of Visalia, California to supply the facilities with thermal and electrical energy costs that management believes will be 50%-80% below typical facilities that are fueled by natural gas. HBSE also plans to employ a value added process platform that is designed to provide greater financial risk mitigation compared to standard facilities, by producing value added salable end products in addition to ethanol and bio-diesel fuels. HBSE believes the ethanol industry has substantial potential for growth.
The President of HBSE, Claude Luster III, said "The location and logistical attributes of the 90-acre Port of Morrow site will help give HBSE an advantage in most cost effectively producing these fuels and delivering them to consumers especially on the west coast of the United States. In combination with the Port of Morrow site, our cost-mitigating approach and vertically integrated technology are perfectly adapted for the production of these bio-fuels and should allow HBSE to compete effectively in this rapidly growing industrial market."
About Market Pulse
Market Pulse LLC, the owner and operator of Market-Pulse.com (collectively referred to as "MP"), is a leading investor relations firm whose primary focus is promoting awareness among brokers, investors, and others in the investment community who are interested in small and micro-cap companies. MP is dedicated to helping publicly traded companies gain the exposure they need to move forward with the development of their business plans. MP's goal is to feature equity investments in micro or small capitalization companies that have the potential for long-term appreciation. MP provides investors with a complete suite of online interactive financial data and tools that includes quotes, charts, company profiles, news, market commentary and SEC filings, just to name a few. MP offers a free financial newsletter. To subscribe or get more information, visit our home page located at www.market-pulse.com.
Information contained herein is the opinion of MP and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP's analyses and/or parties related to those companies. MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.
MP, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis. Information regarding companies which MP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.
You should be aware that MP is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating MP's statements regarding a company. MP has been compensated in free trading shares of common stock, available for public trading as follows: Human BioSystems compensation from the company: six hundred seventy five thousand free trading shares of stock in Human BioSystems already received from the company. In addition, MP in the open market previously purchased one hundred thousand shares of stock in Human BioSystems for a total purchase price of eight thousand forty dollars. To date, MP has sold zero shares of stock in Human BioSystems. MP's officers and directors reserve the right to buy additional shares of the companies discussed in this opinion and may profit in the event those shares rise in value. When MP receives free trading shares as compensation for a profiled company, MP may sell part or all of any such shares during the period in which MP is performing such services.